Measuring Fibrosis in Mice: FibroScan, PRO-C3, ELF Score
Cross the preclinical-clinical gap with the same measures as trials. Non-invasive biomarkers: FibroScan (CAP/VCTE), PRO-C3, ELF score for MASH fibrosis.
Lead: The biggest difference between preclinical studies (animal experiments) and clinical trials is the timing and invasiveness of evaluation. In animal experiments, it is common to remove and evaluate the liver at necropsy on the final day, but performing repeated liver biopsies in human clinical trials is ethically and practically difficult. Today, non-invasive devices such as FibroScan® and blood biomarkers are widely used in clinical settings for screening, patient stratification, and exploratory evaluation. In this article, we describe how to align preclinical mouse studies with these "clinical measures" to support translational research.
Key Takeaways
- Measurement principle of human clinical standard FibroScan (VCTE/CAP)
- Alternative means to perform equivalent evaluation in mice (MRI-PDFF, Micro-elastography)
- Serum biomarkers capturing "Movement of Fibrosis" (PRO-C3, ELF Score)
1. Widely Used Clinical NIT: FibroScan® (VCTE/CAP)
Echosens' FibroScan® is a widely used non-invasive imaging device for liver stiffness and steatosis assessment, and is commonly used in MASH/NASH and fibrosis clinical trials for screening, patient stratification, and exploratory readouts (the exact role depends on trial design; liver biopsy and MRE remain reference standards for definitive staging)[ref-vcte-cap]. The ability to measure both parameters simultaneously in just a few minutes is one of its practical strengths.
1. Liver Stiffness Measurement (LSM)
- Technology: VCTE (Vibration-Controlled Transient Elastography)
- Unit: kPa (kilopascal)
- Meaning: Measures "stiffness" of the liver. Since it hardens as fibrosis progresses, it correlates with fibrosis stage (F0-F4).
2. Controlled Attenuation Parameter (CAP)
- Technology: Ultrasonic attenuation measurement
- Unit: dB/m (decibel/meter)
- Meaning: Measures "fat amount (Steatosis)" of the liver. It is an extremely important endpoint for evaluating Lipid reduction effects by drugs in metabolic diseases like MASH.
2. Can FibroScan be Used in Mice?
To conclude, you cannot apply the clinical FibroScan probe directly to mice (because the probe diameter is larger than the mouse liver). However, alternative technologies exist to measure "the same physical quantities (stiffness and fat amount)".
Alternative 1: MRI-PDFF (Proton Density Fat Fraction)
Preclinical Standard for "Fat Quantification"
- Principle: Uses MRI to separate and quantify proton signals of water and fat in the liver.
- Benefits:
- Visualizes liver fat across the whole organ as a map (reduces sampling error).
- Shows moderate-to-high correlation with FibroScan CAP values (correlation magnitude is study-, population-, and acquisition-dependent)[ref-mri-vs-te][ref-cap-mri-pdff]; agreement on change magnitude is limited in some reports.
- Since it is completely non-invasive, the same individual can be measured every few weeks to track fat-reduction trajectories. A 30% relative MRI-PDFF decline has been associated with histological improvement and fibrosis improvement[ref-mri-pdff-30].
Alternative 2: Micro-elastography (Small Animal Elastography)
Measuring "Stiffness"
- Some manufacturers sell high-frequency ultrasound elastography dedicated to small animals, allowing measurement of mouse liver stiffness (kPa).
- However, technical difficulty such as anesthesia depth and respiratory synchronization is high, and introduction costs tend to be high.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
3. Serum Biomarkers: PRO-C3 and ELF Score
Methods measuring fibrosis dynamics with "blood" rather than "images" are also attracting attention due to high correlation with clinical practice.
PRO-C3 (Type III Collagen Formation Marker)
- "Is fiber being created now?"
- Conventional hydroxyproline quantification measures the total accumulated (past) collagen.
- In contrast, PRO-C3 measures the pro-peptide (neo-epitope) released during type III collagen synthesis, and is positioned as a dynamic biomarker reflecting ongoing fibrogenesis[ref-proc3-neo].
- The ADAPT score (PRO-C3 + age + diabetes + platelet count) has been evaluated against MRE-assessed fibrosis and in NASH screening populations[ref-proc3-mre][ref-proc3-adapt]. PRO-C3 is best treated as an exploratory / supportive biomarker for fibrogenic activity, rather than a stand-in for histological readouts.
ELF™ Score (Enhanced Liver Fibrosis Score)
- An algorithm combining three markers (HA, PIIINP, TIMP-1)[ref-elf-analytical].
- The ELF Test received FDA De Novo authorization as a prognostic indicator for NASH disease progression[ref-elf-siemens][ref-elf-product]. This is a prognostic authorization and is not equivalent to a qualified surrogate endpoint for clinical trials (the regulatory discussion around surrogate endpoints — for example the FDA's Letter of Intent acceptance for VCTE-LSM — proceeds on a separate track)[ref-fda-vcte-loi].
- Measuring ELF's three constituent markers in mice via ELISA is feasible, but species, assay-system, unit, and cutoff differences mean these mouse readouts should be treated as a translational alignment tool, not as direct numerical comparison with clinical ELF values.
- Complete guide: ELF Score: Non-Invasive Biomarker for MASH Liver Fibrosis (formula, clinical cutoffs, and preclinical translation examples)
4. Proposal: Reducing Reliance on End-of-Study Necropsy Endpoints
Traditional mouse studies have relied heavily on cross-sectional designs centered on "end of dosing → necropsy of all animals → tissue analysis," with the final-day necropsy / end-of-study tissue endpoint as the dominant readout. However, incorporating non-invasive biomarkers enables Longitudinal studies like the following.
- Before/After Comparison: Since the rate of change (% change) from baseline for each individual can be calculated, the influence of individual differences (variability) can be minimized.
- Prevention of Dropouts: If it turns out "not working" in the interim progress, it becomes material for judging to modify the protocol early.
Conclusion: Bridging the Translational Gap
"Data measured by grinding mouse liver" alone is insufficient to predict drug efficacy in humans. Keeping FibroScan (CAP/LSM) and PRO-C3 used in clinical trials in mind, and incorporating MRI-PDFF and serum markers that correlate with them from the preclinical stage. This becomes the bridge that saves your drug discovery project from the "Valley of Death."
Further Reading
- Pathological Evaluation Methods
- Choosing Models for Clinical Trials
Comparison Table of Methods
| Metric | FibroScan (CAP) | MRI-PDFF | PRO-C3 |
|---|---|---|---|
| Target | Fat Amount (dB/m) | Fat Amount (%) | Fibrogenesis (ng/mL) |
| Subject | Human (Clinical) | Human/Mouse | Human/Mouse |
| Invasiveness | Non-invasive | Non-invasive | Blood sampling only |
| Resolution | Medium (Local) | High (Whole organ map) | None (Systemic total) |
| Cost | Low (if device available) | High (MRI fee) | Medium (ELISA kit) |
| Role in clinical practice | Widely used non-invasive evaluation device (biopsy / MRE still referenced for definitive staging) | Moderate-to-high correlation with CAP / histology (study-dependent) | Exploratory / supportive biomarker; best used alongside histology |
References
Foundational Literature
- Siddiqui MS, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(1):156-163. PubMed PMID 29705261 / DOI:
10.1016/j.cgh.2018.04.043 - Reeder SB, et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging. 2011;34(4):729-749. PubMed PMID 21928307 / DOI:
10.1002/jmri.22580 - Leeming DJ, et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther. 2013;38(9):1086-1096. PubMed PMID 24099471 / DOI:
10.1111/apt.12438
MRI-PDFF / CAP / NITs
- MRI-based assessments vs transient elastography in NAFLD. Diabetes Care. 2020. PubMed PMID 33108854 / DOI:
10.2337/dc20-0981 - MRI-PDFF 30% relative decline and fibrosis regression. Gut. 2021. PubMed PMID 33883248 / DOI:
10.1136/gutjnl-2021-324264 - CAP monitoring versus MRI-PDFF clinically relevant decline. PubMed PMID 37249034
- U.S. FDA. Acceptance of a Letter of Intent (LOI) for VCTE-LSM as a reasonably likely surrogate endpoint candidate for MASH (regulatory communication / FDA official notice).
PRO-C3 / ECM Turnover
- PRO-C3 and MRE-assessed fibrosis in NAFLD. Hepatology. 2019. PubMed PMID 30859582 / DOI:
10.1002/hep.30455 - PRO-C3 / ADAPT in CENTAUR screening population. JHEP Rep. 2021. PubMed PMID 34454994 / DOI:
10.1016/j.jhepr.2021.100330
ELF Score (Enhanced Liver Fibrosis)
- Analytical performance of ELF Test on Atellica IM Analyzer. 2023. PubMed PMID 37390944
- Siemens Healthineers. FDA De Novo authorization announcement for ELF Test in NASH prognostic risk assessment. Siemens Healthineers official press release
- Siemens Healthineers. ELF Test product page and interpretation ranges. Siemens Healthineers official product page
Related articles
- FIB-4 Score Complete Guide — Formula, age-stratified cutoffs, AASLD/EASL recommendations, FIB-4 + ELF two-step algorithm
- ELF Score Complete Guide
- PRO-C3 and ECM Turnover Biomarkers
- Comprehensive MASLD/MASH Biomarker Review